0PQ.F PROQR THERAPEUTICS EO-04
- Market cap
- EUR 164M
- P/E
- -
- P/B
- 2.15x
- ROE
- -55.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0PQ.F undervalued?
Graham numberThe Graham number of PROQR THERAPEUTICS EO-04 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PROQR THERAPEUTICS EO-04 fundamental analysis
No fundamental analysis for PROQR THERAPEUTICS EO-04 yet.
PROQR THERAPEUTICS EO-04 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein…
Full company profilePROQR THERAPEUTICS EO-04 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PROQR THERAPEUTICS EO-04 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.34M | 3.59M | 6.51M | 18.9M | 15.9M | 21.6M |
| Operating Income | -57.2M | -65.2M | -34.8M | -30.5M | -43.4M | -44.9M |
| EBITDA | - | -56.5M | -24.1M | -24.1M | -38.5M | -42.1M |
| Net Income | -60.7M | -64.4M | -28.1M | -27.8M | -42.2M | -44.2M |
| EPS | -0.85 | -0.80 | -0.35 | -0.26 | -0.40 | -0.31 |
| Balance Sheet | ||||||
| Total Assets | 210M | 171M | 138M | 168M | 113M | 134M |
| Total Liabilities | 96.4M | 105M | 96.5M | 79.4M | 63.4M | 54.1M |
| Shareholders' Equity | 114M | 67.1M | 41.4M | 88.6M | 49.4M | 79.5M |
| Cash & Short-term Investments | 188M | 94.8M | 119M | 149M | 92.4M | 117M |
| Cash Flow | ||||||
| Operating Cash Flow | -26.0M | -68.5M | 21.5M | -36.4M | -52.8M | -46.8M |
| Capital Expenditure | 484K | 708K | 1.37M | 1.42M | 1.02M | 910K |
| Free Cash Flow | -26.5M | -69.2M | 20.2M | -37.8M | -53.8M | -47.7M |
| Ratios | ||||||
| ROE | -53.4% | -96.1% | -67.9% | -31.3% | -85.4% | -55.6% |
| ROA | -29.0% | -37.6% | -20.4% | -16.5% | -37.4% | -33.1% |
| Net Profit Margin | -4,549.8% | -1,792.5% | -431.7% | -146.9% | -265.2% | -204.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PROQR THERAPEUTICS EO-04 dividends
PROQR THERAPEUTICS EO-04 has not paid dividends in the last 5 fiscal years.
Who owns PROQR THERAPEUTICS EO-04
- Insiders 17.46%
- Institutions 54.81%
- Public & others 27.74%
- Shares outstanding 141M
- Free float 91.4M
PROQR THERAPEUTICS EO-04 company profile
- Company name
- PROQR THERAPEUTICS EO-04
- Ticker
- 0PQ.F
- ISIN
- NL0010872495
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 186
- Fiscal year end
- December
- Address
- Zernikedreef 9, Leiden, Netherlands, 2333 CK
- Phone
- 31 88 166 7000
- Website
- proqr.com
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PROQR THERAPEUTICS EO-04 management
9- Mr. Daniel Anton de BoerFounder, CEO & Executive Director · born 1983
- Dr. Gerard Platenburg Ph.D.Co-Founder, Chief Scientific Officer & Executive Director · born 1964
- Mr. Dennis HomChief Financial Officer · born 1975
- Ms. Sheila SponseleeChief People & Operations Officer · born 1984
- Ms. Sarah Cue KielyVice President of Investor Relations & Corporate Communications
- Dr. Cristina Lopez Lopez M.D., Ph.D.Chief Medical Officer · born 1976
- Mr. Christopher Hart Ph.D.Chief Data & AI Officer
- Dr. Golnar KarimianHead of Hepatology
- Ms. Sandra van der KolkJunior Financial Controller